Inhibitory effects of Actinidia polygama extract and cyclosporine A on OVA-induced eosinophilia and bronchial hyperresponsiveness in a murine model of asthma.
Actinidia polygama is one of the well known herb used in oriental medicine for treatment of anti-inflammatory and many allergic diseases. Anti-asthmatic effects of A. polygama in the development of OVA-induced eosinophilia and hyperresponsiveness in murine model of asthma have not been fully investigated in vivo. Cyclosporine A (CsA) has been shown to inhibit single allergen-induced allergic inflammation such as eosinophilic and lymphocytic infiltration and mRNA expression for interleukin (IL)-4 and IL-5. Asthma is a chronic inflammatory disease of the mucosa and is associated with excess production of Th2 cytokines and eosinophil influx in lung. To clarify the anti-inflammatory and anti-asthmatic effects of A. polygama and CsA, we examined the influence of A. polygama fructus extract (APF) and CsA on the development of pulmonary eosinophilic inflammation in murine model of asthma. Our results have shown that APF and CsA have profound inhibitory effects on the accumulation of eosinophills into airways, with the reduction of eosinophil and total lung leukocyte number by reducing IL-4, IL-5, IL-13 and IgE levels in the BALF. Moreover, APF decreased eosinophil CCR3 expression and CD11b expression in lung cells. These results indicate that APF has a deep inhibitory effect on airway inflammation and hyperresponsiveness in murine model of asthma and play a crucial role as an immunomodulator which possess anti-inflammatory and anti-asthmatic property by modulating the relationship between Th1/Th2 cytokine imbalance.
Lee
Young-Cheol
YC
Department of Herbology, College of Oriental Medicine, Sangji University, Wonju, Republic of Korea. lyc072@sangji.ac.kr
Kim
Seung-Hyung
SH
Seo
Young-Bae
YB
Roh
Seong-Soo
SS
Lee
Jang-Cheon
JC
D029042:Actinidia / Q000737:chemistry*; D000818:Animals; D018927:Anti-Asthmatic Agents; D000906:Antibodies / Q000032:analysis; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D016535:Bronchial Hyperreactivity / Q000139:chemically induced / Q000517:prevention & control*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016572:Cyclosporine / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D004802:Eosinophilia / Q000139:chemically induced / Q000517:prevention & control*; D005434:Flow Cytometry; D051379:Mice; D010047:Ovalbumin / Q000037:antagonists & inhibitors / Q000633:toxicity*; D010936:Plant Extracts / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015842:Serine Proteinase Inhibitors / Q000633:toxicity*
D018927:Anti-Asthmatic Agents; D000906:Antibodies; D010936:Plant Extracts; D012333:RNA, Messenger; D015842:Serine Proteinase Inhibitors; D016572:Cyclosporine; D010047:Ovalbumin